Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2021 · 10-Q
Revenue$5.77M$5.77M+28.3% vs Q1 2020 Net Income$240.00K$240.00K−66.4% vs Q1 2020 EPS Diluted$0.13$0.13−75.9% vs Q1 2020 Gross Profit$2,255,000−1.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow-$2,291,000N/M Free Cash Flowderived-$2,343,000N/M Margins · derivedGross margin39.1%−11.9 pt vs Q1 2020
Operating margin-11.5%+27.9 pt vs Q1 2020
Net margin4.2%−11.7 pt vs Q1 2020
ended Jun 30, 2020 · filed Aug 14, 2020 · 45 d after period end